

# Archives of Disease in Childhood

## Therapeutic hypothermia for mild neonatal encephalopathy: A systematic review and meta-analysis

Journal:	<i>Archives of Disease in Childhood</i>
Manuscript ID	fetalneonatal-2018-315711.R2
Article Type:	Short research report
Edition:	not in use
Date Submitted by the Author:	26-Nov-2018
Complete List of Authors:	Kariholu, Ujwal; Imperial College Healthcare NHS Trust, Neonatology; Centre for Perinatal Neurosciences, Imperial College, Dept. of Paediatrics Montaldo, Paolo; Imperial College London and Imperial Neonatal Service, Centre for Perinatal Neuroscience, Department of Paediatrics Markati, Theodora; Centre for Perinatal Neurosciences, Imperial College, Dept. of Paediatrics Lally, Peter; Centre for Perinatal Neurosciences, Imperial College, Dept. of Paediatrics Pryce, Russell; Centre for Perinatal Neurosciences, Imperial College, Dept. of Paediatrics; Medway Hospitals NHS Trust Teiserskas, Justinas; Imperial College Healthcare NHS Trust, Neonatology Liow, Natasha; Imperial College Healthcare NHS Trust, Neonatology Oliveira, Vania; Imperial College London, Medicine Soe, Aung; Medway Trust, Neonatal Unit Shankaran, Seetha; Wayne State UniversityChildrens Hospital of MI, PediatricsNeonatology Thayyil, Sudhin; Imperial College London, Medicine
Keywords:	Neurodevelopment, Neurodisability, Outcomes research, Neonatology, Imaging

SCHOLARONE™  
Manuscripts

1  
2  
3 **Therapeutic hypothermia for mild neonatal encephalopathy: A**  
4 **systematic review and meta-analysis**  
5  
6  
7

8 Ujwal Kariholu<sup>1,2</sup>, Paolo Montaldo<sup>1</sup>, Theodora Markati<sup>1,2</sup>, Peter J Lally<sup>1</sup>,  
9 Russell Pryce<sup>1,3</sup>, Justinas Teiserskas<sup>2</sup>, Natasha Liow<sup>2</sup>, Vânia Oliveira<sup>1</sup>, Aung  
10 Soe<sup>3</sup>, Seetha Shankaran<sup>4</sup>, Sudhin Thayyil<sup>1</sup>  
11  
12  
13  
14  
15

16 <sup>1</sup>Centre for Perinatal Neuroscience, Imperial College London, London, UK

17 <sup>2</sup>Neonatal Unit, Imperial College Healthcare NHS Trust, London, UK

18 <sup>3</sup>Neonatal Unit, Medway Hospital NHS Trust, Gillingham, Kent, UK

19 <sup>4</sup>Neonatal Perinatal Medicine, Wayne State University, Michigan, USA  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Correspondence

32 Sudhin Thayyil MD, DCH, FRCPCH, PhD

33 Centre for Perinatal Neuroscience

34 Room 529 Hammersmith House

35 Hammersmith Campus

36 Imperial College London

37 Du cane Road, London W12 0HS

38 E mail: [s.thayyil@imperial.ac.uk](mailto:s.thayyil@imperial.ac.uk)

39 Tel: 020 3313 3270

40 Fax: 020 3313 1122  
41  
42  
43  
44  
45  
46  
47

48 **Key words:** Hypoxic ischaemic encephalopathy, Therapeutic Hypothermia,  
49 Meta-analysis, Newborn  
50  
51  
52  
53

54 **Word count:** Abstract:190; Main text:1215  
55  
56  
57  
58  
59  
60

## Abstract

**OBJECTIVES:** To examine if therapeutic hypothermia reduces the composite outcome of death, moderate or severe disability at 18 months or more after mild neonatal encephalopathy (NE).

**DATA SOURCE:** MEDLINE, Cochrane database, Scopus and ISI Web of Knowledge databases, using hypoxic ischemic encephalopathy', 'newborn', and 'hypothermia' and 'clinical trials' as medical subject headings and terms. Manual search of the reference lists of all eligible articles and major review articles, and additional data from the corresponding authors of selected articles.

**STUDY SELECTION:** Randomised and quasi-randomised controlled trials (RCT) comparing therapeutic hypothermia with usual care.

**DATA EXTRACTION:** Safety and efficacy data extracted independently by two reviewers and analysed.

**RESULTS:** We included the data on 117 babies with mild NE inadvertently recruited to five cooling trials (2 whole-body cooling and 3 selective head cooling) of moderate and severe NE, in the meta-analysis. Adverse outcomes occurred in 11/56 (19.6%) of the cooled babies and 12/61 (19.7%) of the usual care babies (Risk Ratio 1.11 (95% Confidence intervals 0.55 to 2.25).

**CONCLUSIONS:** Current evidence is insufficient to recommend routine therapeutic hypothermia for babies with mild encephalopathy and significant benefits or harm cannot be excluded.

### What is already known on this topic?

- Therapeutic hypothermia for 72 hours reduces death and improves survival without disability during infancy and mid childhood after moderate or severe neonatal encephalopathy and is now the standard care therapy for these babies.
- A therapeutic drift to extending the cooling therapy to babies with mild encephalopathy has been reported in the UK and other high-income countries.

### What this study adds?

- Adverse neurological outcomes at 18 months or more, occur in 20% of babies with mild encephalopathy.
- Pooled data from five cooling trials inadvertently recruiting babies with mild encephalopathy do not exclude significant therapeutic benefits or harm

## Introduction

Although therapeutic hypothermia is only recommended as the standard therapy for babies with moderate or severe neonatal encephalopathy (NE), a therapeutic creep has been reported worldwide<sup>1</sup>. In the UK, 67% of the cooling centres routinely cool babies with mild NE, and at times for shorter durations than the recommended 72 hours for moderate or severe NE<sup>1</sup>. There are concerns with such practices, as the cessation of cooling therapy prior to 24 hours following an apparent clinical recovery may be associated with residual brain injury and adverse outcomes<sup>2</sup>. Furthermore, cooling therapy in the absence of NE may induce apoptosis<sup>3</sup>. In contrast to the systematic review of cooling in mild NE reported by Conway et al, our review includes additional published studies, as well as raw data provided by the study authors<sup>4</sup>.

In this systematic review and meta-analysis, we examined the efficacy of cooling therapy in improving neurological outcomes after mild NE.

## Methods

We used the Cochrane methodology for the review. Three investigators (UK/JT/ST) searched the MEDLINE, Cochrane database, Scopus and ISI Web of Knowledge databases (1995 to 2018) using the keywords 'hypoxic ischemic encephalopathy', 'newborn', and 'hypothermia' and clinical trials as study type.

All randomised (RCT) and quasi-randomised controlled clinical trials

1  
2  
3 comparing selective head or whole-body cooling with usual care in term or  
4 near-term infants ( $\geq 36$  weeks) with mild NE after perinatal asphyxia were  
5 eligible. Perinatal asphyxia required at least one of the following criteria:  
6 evidence of intra-partum catastrophe, fetal or neonatal metabolic acidosis  
7 and/or resuscitation at birth. Mild NE was not defined separately but was  
8 based on a clinical neurological examination performed within six hours of  
9 birth, as reported in the individual studies. Primary outcome was the  
10 composite of death or moderate or severe disability at or beyond 18 months of  
11 age.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Three authors (UK/RP/TM) independently extracted the raw data from the full  
27 text or supplementary information of the eligible studies. Additional data were  
28 obtained from the corresponding authors. Two assessors (NL/RP)  
29 independently examined the study quality using the Cochrane risk of bias tool  
30 (<https://methods.cochrane.org/bias/resources/cochrane-risk-bias-tool>) (eTable  
31 1). We used a fixed effects model for meta-analysis (RevMan version 5.1.4).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 Results

43 We identified 91 papers on initial screening, of which fourteen RCTs met the  
44 inclusion criteria. Seven included mild NE, of which outcome data were  
45 available from five (eFigure 1).  
46  
47  
48  
49  
50  
51  
52  
53

54 The inclusion criteria for participants in the studies were similar and primarily  
55 based on a modified Sarnat clinical encephalopathy examination. Thayyil et al  
56 used the Thompson encephalopathy score<sup>5</sup>, while Gluckman et al (Coolcap  
57  
58  
59  
60

1  
2  
3 Trial) required abnormal amplitude integrated electroencephalography (aEEG)  
4  
5 in addition to the clinical neurological examination<sup>6</sup>. Hence, the Coolcap trial<sup>6</sup>  
6  
7 included eight babies with mild NE of whom five had moderate aEEG voltage  
8  
9 abnormalities and three had severe voltage abnormalities.  
10

11  
12  
13  
14 Two studies used whole-body cooling and three used selective head cooling.  
15  
16 The cooling devices used in these studies were ice packs (n=1) and phase  
17  
18 change material (n=1) for the whole-body cooling group (target core  
19  
20 temperature 33.0 to 34.0°C) and cooling caps (n=3) for the selective cooling  
21  
22 group (target core temperature 34.5 to 35.0°C) (Table 1).  
23  
24  
25  
26  
27

28  
29 All except one study was of fair quality (eTable 1). Infants in the control group  
30  
31 were cared for under overhead radiant warmers, which were servo-controlled  
32  
33 to the infant's abdominal skin temperature to maintain normothermia, although  
34  
35 the individual temperature profiles were not available. Infants in both groups  
36  
37 received similar clinical care, monitoring of vital signs and surveillance for  
38  
39 organ dysfunction, irrespective of the intervention.  
40  
41  
42  
43  
44

45  
46 Primary outcome (death or moderate or severe disability at ≥18 months of  
47  
48 age) was available from 117 of 133 babies (Table 1) for meta-analysis (56  
49  
50 cooled vs 61 non-cooled). Pooled data did not show any significant difference  
51  
52 in the adverse outcomes between the two groups (11/56 (19.6%) of the  
53  
54 cooled babies and 12/61 (19.7%) of the usual care babies (Risk Ratio (RR)  
55  
56 1.11 (95% Confidence intervals 0.55 to 2.25). No statistical heterogeneity was  
57  
58 observed on meta-analysis ( $\chi^2=2.31$ ;  $p=0.68$ ) (Figure 1). **The data on other**  
59  
60

1  
2  
3 short-term morbidities were not available.  
4  
5  
6  
7

## 8 Discussion

9  
10 The pooled data, including a total of 117 babies with mild NE, did not show a  
11 reduction in adverse outcomes (RR 1.12, 95% CI 0.42 to 2.98). However, the  
12 confidence intervals were wide, suggesting that a significant benefit or harm  
13 from cooling therapy cannot be excluded. The observation of adverse  
14 outcomes in 20% of the babies (in both usual care and cooled groups)  
15 confirms the emerging concerns about the 'non-benign' nature of mild NE.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 It is possible that the underlying mechanism of brain injury after moderate or  
27 severe NE may be different to that after mild NE and so the therapeutic  
28 efficacy of hypothermia cannot be taken for granted in this population. For  
29 example, secondary energy failure is seen in preclinical models of moderate  
30 or severe NE, which is prevented by therapeutic hypothermia,<sup>7</sup> and this is not  
31 thought to be a feature of mild NE. Furthermore, most investigators have  
32 reported that the patterns of brain injury in mild NE are different to those of  
33 moderate or severe NE, indicating the underlying mechanisms may be  
34 different<sup>8</sup>.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 The number of babies with adverse outcomes, and the total number of studies  
50 included in our meta-analyses is different to that of Conway et al<sup>4</sup>. However, it  
51 did not affect the overall pooled data. As the raw data were not available from  
52 some of the published papers, we obtained these from the corresponding  
53 authors, which may explain these differences.  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 Our systematic review has some limitations. Although the included trials were  
7  
8 of high quality, they were designed to recruit only babies with moderate or  
9  
10 severe NE, and the babies with mild NE were inadvertently recruited.  
11  
12 Therefore, it is possible that these babies had additional or alternative  
13  
14 pathologies, for example stroke, and hence may not be representative of the  
15  
16 typical mild NE population. Secondly, there is no uniformly accepted definition  
17  
18 of mild NE, particularly when the diagnosis is made within 6 hours of birth,  
19  
20 and it is likely that criteria varied within the individual trials. This may explain  
21  
22 the surprisingly high event rates (death or moderate or severe disability) and  
23  
24 the lack of treatment effect of hypothermic neuroprotection in our meta-  
25  
26 analysis.  
27  
28  
29  
30  
31  
32

33 Data from studies that included babies with mild NE have variable results. In  
34  
35 a prospective study of 63 non-cooled babies with mild NE on modified Sarnat  
36  
37 examination performed within 6 hours of birth, Chalak et al reported adverse  
38  
39 outcome at 18-22 months in 16% of babies<sup>9</sup>. Only one baby with mild NE  
40  
41 developed seizures after six hours of age and progressed to moderate NE<sup>9</sup>. In  
42  
43 contrast, Lally et al found no adverse outcome in cooled mild NE babies  
44  
45 recruited to the MARBLE (Magnetic Resonance Biomarkers in Neonatal  
46  
47 Encephalopathy) study<sup>10</sup>. In the secondary analysis of this study, cooling  
48  
49 babies with mild NE was associated with improved magnetic resonance  
50  
51 spectroscopy biomarkers<sup>11</sup>. Well designed and adequately powered  
52  
53  
54 randomised controlled trials are needed to address the risks, benefits, and  
55  
56 efficacy of therapeutic hypothermia in mild NE.  
57  
58  
59  
60

## Conclusion

Although up to 20% of babies with mild NE may have the adverse outcome of death or moderate or severe disability at 18 months of age, current evidence is insufficient to recommend routine therapeutic hypothermia for this condition. Our meta-analysis suggests that significant benefits or harm of therapeutic hypothermia in mild NE cannot be excluded. Therapeutic hypothermia in mild NE should not be considered as the standard of care until further evidence from adequately powered clinical trials is available.

## Conflict of interest

The authors declare no conflict of interest

## Contributions

UK searched the literature, extracted the data, and drafted the manuscript along with PM and P.J.L. RP and TM extracted the data and examined the study quality with NL. JT searched the literature. VO, AS and SS interpreted the data and assisted in developing the manuscript. ST conceived the idea, performed the meta-analysis and supervised the entire work.

## Funding

PM is funded by an MRC doctoral fellowship, VO by an NIHR doctoral fellowship and P.J.L. by an NIHR clinical trials fellowship. **This research was supported by the NIHR Biomedical Research Centre based at Imperial**

1  
2  
3 College London. The views expressed are those of the author(s) and not  
4  
5 necessarily those of the NIHR or the Department of Health  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only

Table 1. Details of studies meeting the eligibility criteria

Study	N*	GA	Evidence of asphyxia	Neurological exam	Intervention	Device	Age at F/U	Definition of adverse outcome
Jacobs 2011 <sup>12</sup>	40	>35	A/S <5 or resuscitation at 10min; Cord pH <7.0; BD >12	Modified Sarnat staging	Whole body cooling (33.0 to 34.0°C) for 72 h	Ice packs	24 mo	Mortality or major sensorineural disability (Bayley II Psychomotor or mental development index <2SD, cerebral palsy, blindness or deafness) at 2 years of age.
Zhou 2010 <sup>13</sup>	39	≥37	A/S <6 or need for resuscitation at 5min; Cord pH <7.0 or BD >16.	Modified Sarnat staging	Selective head cooling (rectal temp 34.5 to 35.0°C) for 72 h	Cooling cap	18 mo	Gesell Child Development Age Scale (Gross Motor Function Classification System level 3-5 or DQ <70)
Thayyil 2013 <sup>5</sup>	19	≥36	A/S <6 or need for resuscitation at 5min	Thompson encephalopathy score	Whole body cooling (33.0 to 34.0°C) for 72 h	Phase change material	42 mo	Cerebral palsy, visual or hearing impairment, composite motor score <82 or composite cognitive score <85 on Bayley III
Battin 2001 <sup>14</sup>	11	>37	A/S <6 at 5min; Cord pH <7	Clinical encephalopathy	Selective head cooling either:	Cooling cap	18 mo	Death, cerebral palsy, Bayley scores > 2 standard deviations from the norm,

				(lethargy/stupor, hypotonia, abnormal reflexes including absent/weak suck)	Minimally cooled (36.5 to 36.0°C) or Mildly cooled (35.9 to 35.5°C) for 72 h			blindness, or hearing impairment requiring amplification, at 2 years of age.
Gluckman 2005 <sup>6</sup>	8	≥36	A/S <6 or resuscitation at 10min; pH<7 or BD >16; abnormal aEEG	Modified Sarnat staging	Selective head cooling (34.5 +/- 0.5°C) for 72 h	Cooling cap	18 mo	Severe neurodevelopmental disability was defined as (1) gross motor function classification levels 3 through 5 (non-ambulatory, sits with support applied to lower back, or limited or no self-mobility), (2) Bayley Mental Developmental Index of 70, or (3) bilateral cortical visual impairment; at 18 months of age.
**Lin 2006 <sup>15</sup>	14	≥37	A/S <6 at 5min; pH <7 or BD >15	Decreased muscle tone, lethargy, coma, or seizures	Selective head cooling with rectal temp 34.5 to 35.0°C for 72 h	Cooling cap	10d	Neonatal Behavioural Neurological Assessment score at 7–10 days of life, CT scan grading at 5–7 postnatal days. No long-term follow-up available.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

***Eicher 2005 <sup>16</sup>	2	≥36	cord gas pH <7.0 or BD >13, initial infant gas pH <7.1, Apgar score 5 at 10 minutes or continued resuscitation after 5 minutes	Any two of: posturing, seizures, autonomic dysfunction, or increased /decreased abnormalities of tone, reflexes, or state of consciousness.	Whole body cooling (33.0 to 34.0°C) for 48 h	Blanketrol	12 mo	Severely abnormal was defined as >2 standard deviations from mean, moderately abnormal as >1 and ≤2 S.D on neurodevelopmental tests of motor function (Bayley Psychomotor Development Index, Vineland gross motor) and cognitive function (Bayley II)
---------------------------------	---	-----	---	--	--	------------	-------	---

\*number of babies with mild encephalopathy; \*\*not included in the meta-analysis

A/S=Apgar score; BD=Base deficit; DQ=Developmental quotient, d=days, mo=months, aEEG=amplitude integrated electroencephalography.

**\*\*Not included in the meta-analysis as the authors did not provide the data on babies with mild encephalopathy.**

**\*\*\*2 babies with mild encephalopathy recruited; 1 withdrew from the study and other lost to follow up (Data provided by the corresponding author). Hence not included in the meta-analysis.**

1  
2  
3  
4  
5 Figure 1. Effect of cooling on death or moderate or severe disability after mild encephalopathy (SHC: Selective head cooling; WBC:  
6  
7 Whole body cooling)  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Confidential: For Review Only

## References

1. Oliveira V, Singhvi DP, Montaldo P, et al. Therapeutic hypothermia in mild neonatal encephalopathy: a national survey of practice in the UK. *Arch Dis Child Fetal Neonatal Ed* 2017;103:F388-F390
2. Lally PJ, Montaldo P, Oliveira V, et al. Residual brain injury after early discontinuation of cooling therapy in mild neonatal encephalopathy. *Arch Dis Child Fetal Neonatal Ed* 2017;103:F383-F387.
3. Koo E, Sheldon RA, Lee BS, Vexler ZS, Ferriero DM. Effects of therapeutic hypothermia on white matter injury from murine neonatal hypoxia-ischemia. *Pediatr Res* 2017;82:518-26.
4. Conway JM, Walsh BH, Boylan GB, Murray DM. Mild hypoxic ischaemic encephalopathy and long term neurodevelopmental outcome - A systematic review. *Early Hum Dev* 2018;120:80-7.
5. Thayyil S, Shankaran S, Wade A, et al. Whole-body cooling in neonatal encephalopathy using phase changing material. *Arch Dis Child Fetal Neonatal Ed* 2013;98:F280-1.
6. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet* 2005;365:663-70.
7. Thoresen M, Penrice J, Lorek A, et al. Mild hypothermia after severe transient hypoxia-ischemia ameliorates delayed cerebral energy failure in the newborn piglet. *Pediatr Res* 1995;37:667-70.
8. **Walsh BH, Inder TE. MRI as a biomarker for mild neonatal**



- 1  
2  
3 encephalopathy. *Early Hum Dev* 2018;120:75-79  
4  
5  
6 9. Chalak LF, Nguyen KA, Prempunpong C, et al. Prospective research in  
7  
8 infants with mild encephalopathy identified in the first six hours of life:  
9  
10 neurodevelopmental outcomes at 18-22 months. *Pediatr Res* 2018. doi:  
11  
12 10.1038/s41390-018-0174-x. [Epub ahead of print]  
13  
14  
15 10. Lally PJ, Montaldo P, Oliveira V, et al. Magnetic resonance  
16  
17 spectroscopy assessment of brain injury after moderate hypothermia in  
18  
19 neonatal encephalopathy: a prospective multicentre cohort study.  
20  
21 *Lancet neurology* 2018. doi: 10.1016/S1474-4422(18)30325-9. [Epub  
22  
23 ahead of print]  
24  
25  
26  
27 11. Montaldo P, Lally PJ, Oliveira V, et al. Therapeutic hypothermia  
28  
29 initiated within 6 hours of birth is associated with reduced brain injury  
30  
31 on MR biomarkers in mild hypoxic-ischaemic encephalopathy: a non-  
32  
33 randomised cohort study. *Arch Dis Child Fetal Neonatal Ed* 2018. doi:  
34  
35 10.1136/archdischild-2018-316040. [Epub ahead of print]  
36  
37  
38  
39  
40 12. Jacobs SE, Morley CJ, Inder TE, et al. Whole-body hypothermia for  
41  
42 term and near-term newborns with hypoxic-ischemic encephalopathy: a  
43  
44 randomized controlled trial. *Arch Pediatr Adolesc Med* 2011;165:692-  
45  
46 700.  
47  
48  
49  
50 13. Zhou WH, Cheng GQ, Shao XM, et al. Selective head cooling with mild  
51  
52 systemic hypothermia after neonatal hypoxic-ischemic encephalopathy:  
53  
54 a multicenter randomized controlled trial in China. *J Pediatr* 2010;157:  
55  
56 367-72.  
57  
58  
59 14. Battin MR, Dezoete JA, Gunn TR, Gluckman PD, AJ G.  
60

- 1  
2  
3 Neurodevelopmental outcome of infants treated with head cooling and  
4 mild hypothermia after perinatal asphyxia. *Pediatrics* 2001;107:480-4.  
5  
6  
7  
8  
9 15. Lin Z, Yu H, Lin J, Chen S, Liang Z, Zhang Z. Mild hypothermia via  
10 selective head cooling as neuroprotective therapy in term neonates  
11 with perinatal asphyxia: an experience from a single neonatal intensive  
12 care unit. *J Perinatol* 2006;26:180-4.  
13  
14  
15  
16  
17  
18 16. Eicher D, Wagner C, Katikaneni L, et al. Moderate hypothermia in  
19 neonatal encephalopathy: efficacy outcomes. *Pediatr Neurol* 2005;32:  
20 11-7.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





Figure 1. Effect of cooling on death or moderate or severe disability after mild encephalopathy (SHC: Selective head cooling; WBC: Whole body cooling)

292x73mm (144 x 144 DPI)

eFigure 1. Flow chart of the literature search



eTable 1. Risk of bias and overall quality of the clinical trials meeting the inclusion criteria

Study name	Random sequence generation	Allocation concealment	Selective reporting	Blinding of participants/personnel <sup>a</sup>	Blinding of outcome	Incomplete outcome	Other bias	Quality
Battin 2001	Low risk	Unclear risk	Low risk	High risk	Unclear risk	Low risk	Low risk	Fair
Gluckman 2005 <sup>c</sup>	Low risk	Low risk	Low risk	High risk	Low risk	Low risk	Low risk	Fair
Zhou 2010	Low risk	Low risk	Unclear risk	High risk	Low risk	High risk <sup>b</sup>	Low risk	Poor
Jacobs 2011	Low risk	Low risk	Unclear risk	High risk	Low risk	Low risk	Low risk	Fair
Thayyil 2013 <sup>c</sup>	Low risk	Low risk	Low risk	High risk	Low risk	Low risk	Low risk	Fair
*Lin 2006	High risk	High risk	Unclear risk	High risk	Unclear risk	Unclear risk	High risk	Poor
**Eicher 2005 <sup>c</sup>	Low risk	Low risk	Low risk	High risk	Low risk	Unclear risk	Low risk	Fair

<sup>a</sup>Blinding of intervention is not possible

<sup>b</sup>Disproportionate post-randomisation exclusion in the intervention arm

<sup>c</sup>Additional data obtained from the corresponding author on babies with mild encephalopathy and randomisation details

\*Not included in the meta-analysis as the authors did not provide the data on babies with mild encephalopathy.

\*\*2 babies with mild encephalopathy recruited; 1 withdrew from the study and other lost to follow up (Data provided by the corresponding author). Hence not included in the meta-analysis.